Solara Active Pharma Sciences Limited has announced revisions to its key corporate policies following a Board of Directors meeting held on February 06, 2026. The pharmaceutical company updated two critical governance policies to ensure compliance with recent amendments to SEBI regulations.

Policy Amendments Approved

The board considered and approved amendments to two important corporate policies during their meeting. These revisions demonstrate the company's commitment to maintaining robust governance standards and regulatory compliance.

Materiality Disclosure Policy Update

The company amended its "Policy for Determining Materiality of Events/Information for Disclosure to Stock Exchanges" to align with recent amendments in Regulation 30 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015. This policy governs how the company determines which events and information require disclosure to stock exchanges, ensuring transparency for investors and market participants.

Related Party Transaction Policy Revision

The Board members reviewed and adopted the revised "Policy for Governance of Related Party Transactions" in compliance with amendments to Regulation 23 of SEBI (Listing Obligations and Disclosure Requirement) Regulation, 2015. This policy framework ensures proper governance and transparency in transactions between the company and its related parties.

Policy Accessibility

Both amended policies are now available on the company's website at solara.co.in/investor-relations/policies-and-guidelines/, providing stakeholders with easy access to the updated governance frameworks. The company secretary and compliance officer, Pooja Jaya Kumar, signed the regulatory filing confirming these policy updates.

These policy revisions reflect Solara Active Pharma Sciences' ongoing commitment to maintaining high standards of corporate governance and ensuring full compliance with evolving regulatory requirements in the Indian securities market.

Solara Active Pharma Sciences announced its Q3FY26 financial results, reporting revenue of ₹349 crores alongside a consolidated net loss of ₹17.43 crores. The pharmaceutical company's Board of Directors approved the unaudited financial results for the quarter ended December 31, 2025, during their meeting held on February 6, 2026.

Financial Performance Overview

The company's Q3FY26 results demonstrate revenue growth compared to the corresponding quarter of the previous year, with total income reaching ₹349 crores against ₹301.80 crores in Q3FY25. However, the company recorded a consolidated net loss of ₹17.43 crores, marking a significant shift from the ₹8.09 crores profit achieved in the same quarter last year.

Exceptional Charges Impact Operations

A significant factor affecting the quarter's performance was exceptional charges of ₹6.75 crores related to gratuity and compensated absences impact under new labour codes. This one-time charge substantially impacted the company's profitability metrics for the quarter. Before exceptional items, the company reported a loss of ₹10.68 crores compared to a profit of ₹8.09 crores in the corresponding quarter last year.

Nine-Month Performance Analysis

For the nine months ended December 31, 2025, Solara Active Pharma Sciences reported total income of ₹983.16 crores compared to ₹1,013.12 crores in the corresponding period last year. The company recorded a consolidated net loss of ₹17.01 crores for the nine-month period, contrasting with a profit of ₹2.64 crores in the previous year.

Rights Issue and Financial Position

The company continues its rights issue program, having raised ₹311.85 crores out of the total ₹449.95 crores rights issue as of December 31, 2025. This includes ₹157.48 crores from application money and ₹154.37 crores from the first call, with ₹134.99 crores pending from the final call. The company maintains accumulated losses of ₹329.64 crores as of December 31, 2025, with net current liabilities exceeding current assets by ₹92.44 crores.

Strategic Developments and Outlook

Solara Active Pharma Sciences operates primarily in the Active Pharmaceutical Ingredient segment. The Board of Directors had previously approved exploring the demerger of CRAMS and Polymers business into an independent listed entity, leading to the incorporation of wholly owned subsidiary Synthix Global Pharma Solutions Limited on April 29, 2025. The company expects to continue operations on a going concern basis, anticipating adequate cash flows from operations and working capital facility renewals.